ENXTAM:PHARMBiotechs
A Look At Pharming Group (ENXTAM:PHARM) Valuation After Joenja’s Landmark APDS Approval In Japan
Pharming Group (ENXTAM:PHARM) is back on investor radars after Japan’s Ministry of Health, Labour and Welfare approved Joenja for activated PI3K delta syndrome in patients aged 4 and older, including children 4 to 11.
See our latest analysis for Pharming Group.
The Joenja approval in Japan comes after a period where short term share price performance has been softer, with a 30 day share price return showing a decline of 1.21% and a year to date share price return showing a decline of 4.85%,...